What is it about?
Triple-negative breast cancer, being not responsive to hormonal treatment and target therapy, is considered to be the most aggressive molecular subtype of breast cancer. In this retrospective review, we have identified that in addition to the advanced stage of the disease, a high proliferative index (Ki-67) and omission of chemotherapy are associated with a worse survival.
Featured Image
Photo by Angiola Harry on Unsplash
Why is it important?
Cancer staging is the most commonly used prognostic indicator on various types of malignancy. However, even with the same stage, the survival of different patients varies. In this study, we find that in triple-negative breast cancer, in addition to the advanced stage of the disease, a high proliferative index (Ki-67) and lack of chemotherapy are associated with a worse prognosis. Surgery alone is not enough for managing this aggressive type of malignancy.
Perspectives
Triple-negative breast cancer is the most aggressive molecular subtype of breast cancer. In order to improve the survival, more work has to be done in order to identify the best treatment protocol for the patient. As one of the major breast cancer center in Hong Kong, it is my pleasure to present the data from our institute.
Ka Wai Ray Hung
Chinese University of Hong Kong
Read the Original
This page is a summary of: High Ki‐67 proliferation index and lack of chemotherapy are associated with reduced overall survival in patients with triple negative breast cancer: A retrospective cohort in a major breast centre in Hong Kong, Surgical Practice, September 2021, Wiley,
DOI: 10.1111/1744-1633.12527.
You can read the full text:
Contributors
The following have contributed to this page
